Aug 23, 2024 / 06:30AM GMT
Magnus Tolleshaug - Vistin Pharma ASA - Chief Executive Officer
Welcome all to this second quarter 2024 presentation. I will now go through the highlights of the second quarter 2024 results. The revenue in the second quarter ended at NOK106 million versus NOK107 million in the second quarter of 2023. Currency neutral revenue was slightly higher in the quarter compared to the second quarter of 2023 was about 1%. The year-to-date 2024 revenue ended at NOK210 million compared to NOK208 million year-to-date last year.
The second quarter ended with a record high EBITDA of NOK27 million versus NOK20 million in the second quarter of 2023, an increase of 40%. The EBITDA was positively affected by product mix, favorable material cost prices and good cost control in the quarter. The EBITDA year-to-date ended at NOK48 million versus NOK34 million year-to-date at the same time last year, an increase of 42%.
The manufacturing line 2 has been producing according to plan from April, after the unplanned maintenance and repair we had in the first quarter, we also had planned biannual maintenance stop
Q2 2024 Vistin Pharma ASA Earnings Call Transcript
Aug 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers